Business Description
Lyell Immunopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US55083R1041
Share Class Description:
LYEL: Ordinary SharesDescription
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 9.54 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.25 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 0.04 | |||||
Beneish M-Score | -131.5 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -70 | |||||
3-Year EBITDA Growth Rate | 2.7 | |||||
3-Year EPS without NRI Growth Rate | 3.1 | |||||
3-Year FCF Growth Rate | 12.9 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 20.95 | |||||
9-Day RSI | 23.17 | |||||
14-Day RSI | 27.72 | |||||
6-1 Month Momentum % | 30.33 | |||||
12-1 Month Momentum % | -13.79 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 16.51 | |||||
Quick Ratio | 16.51 | |||||
Cash Ratio | 16.27 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.5 | |||||
Shareholder Yield % | 1.59 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -352980.88 | |||||
Net Margin % | -335794.12 | |||||
FCF Margin % | -236295.59 | |||||
ROE % | -32.84 | |||||
ROA % | -28.87 | |||||
ROIC % | -110.87 | |||||
ROC (Joel Greenblatt) % | -161.37 | |||||
ROCE % | -31.68 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1430 | |||||
PB Ratio | 0.6 | |||||
Price-to-Tangible-Book | 0.6 | |||||
EV-to-EBIT | 0.44 | |||||
EV-to-EBITDA | 0.48 | |||||
EV-to-Revenue | -1567.32 | |||||
EV-to-Forward-Revenue | 16311.67 | |||||
EV-to-FCF | 0.66 | |||||
Price-to-Net-Current-Asset-Value | 0.82 | |||||
Price-to-Net-Cash | 0.84 | |||||
Earnings Yield (Greenblatt) % | 227.27 | |||||
FCF Yield % | -44.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LYEL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lyell Immunopharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.068 | ||
EPS (TTM) ($) | -0.9 | ||
Beta | -0.43 | ||
Volatility % | 101.11 | ||
14-Day RSI | 27.72 | ||
14-Day ATR ($) | 0.209696 | ||
20-Day SMA ($) | 2.19375 | ||
12-1 Month Momentum % | -13.79 | ||
52-Week Range ($) | 1.18 - 3.41 | ||
Shares Outstanding (Mil) | 254.94 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Lyell Immunopharma Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Lyell Immunopharma Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Lyell Immunopharma Inc Frequently Asked Questions
What is Lyell Immunopharma Inc(LYEL)'s stock price today?
The current price of LYEL is $1.43. The 52 week high of LYEL is $3.41 and 52 week low is $1.18.
When is next earnings date of Lyell Immunopharma Inc(LYEL)?
The next earnings date of Lyell Immunopharma Inc(LYEL) is 2024-08-08 Est..
Does Lyell Immunopharma Inc(LYEL) pay dividends? If so, how much?
Lyell Immunopharma Inc(LYEL) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |